Pharmaceutical manufacturing facility resumes operations in Himachal Pradesh, India
The drug manufacturing licence for Jackson Labs’ facility in Baddi, Himachal Pradesh, has been restored after a period of suspension. The licence was initially cancelled in June following an incident where several women in Kota, Rajasthan, allegedly died due to spurious oxytocin injections supplied by the company’s unit in Punjab.
The restoration of the licence marks a significant development for the company, which faced regulatory scrutiny and operational halt due to the serious allegations. The suspension had a direct impact on the company’s manufacturing capabilities and reputation within the pharmaceutical sector.
While the details of the conditions for the licence restoration have not been fully disclosed, the move suggests that regulatory authorities are satisfied with the corrective measures or assurances provided by Jackson Labs. This decision is crucial for the company’s operations in Baddi, a key pharmaceutical manufacturing hub.
The incident involving oxytocin injections highlighted the critical importance of quality control and regulatory compliance in pharmaceutical manufacturing. The deaths in Rajasthan had prompted a thorough investigation into the supply chain and manufacturing practices of the involved companies.
The outcome of this situation will be closely watched by other players in the pharmaceutical industry, particularly those operating in similar regulatory environments. The focus remains on ensuring the safety and efficacy of pharmaceutical products through stringent quality checks and adherence to manufacturing standards.
About the Author
